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Influence of Hepatitis G Virus 
Infection on Liver Disease 
I.D. Diamantis 1., E. Kouroumalis 2, 
M. Koulentaki 2, E. Fasler-Kan 1, 
RA. Schmid 3, H.H. Hirsch 4, H. Bt~hler 3, 
K. Gyr 1, M. Battegay 1 
The influence of hepatitis G virus (HGV) infection on 
disease activity in hepatitis C related and unrelat- 
ed liver disease was investigated in 254 individu- 
als using an EIA polymerase chain reaction assay 
for HGV. One hundred patients had chronic hepa- 
titis C, 26 primary biliary cirrhosis, and 30 alcohol- 
ic liver cirrhosis. In addition, 51 hepatitis B surface 
antigen (HBsAg)-positive and 47 anti-hepatitis C vi- 
rus (HCV)-positive blood donors were screened. 
Hepatitis G virus was detected in 18% of patients 
with chronic hepatitis C, 13% of patients with al- 
coholic liver cirrhosis, 11% of patients with primary 
biliary cirrhosis, 10% of anti-HCV-positive blood do- 
nors, and 2% of HBsAg-positive blood donors. Vi- 
rus load and alanine aminotransferase (ALT) levels 
did not differ significantly in patients with HCV 
alone versus patients coinfected with HCV and 
HGV. However, mild liver fibrosis correlated with 
HGV coinfection. Hepatitis G virus did not influence 
ALT levels or liver damage in liver disease unrelat- 
ed to viral infection. 
Hepatitis G virus (HGV) (1) belongs to the Fla- 
viviridae family and has a genomic organization 
similar to that of the hepatitis C virus (HCV) (2). 
Hepatitis G virus has been detected in patients 
with liver diseases such as chronic and acute hep- 
atitis (1, 3-5) and in patients with risk factors of 
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parenteral exposure, .g. multiple transfusions (6) 
and intravenous drug use (7). Hepatitis G virus 
was also detected in patients with no evidence of 
liver disease and without known risk factors, such 
as volunteer blood donors. Recent reports uggest 
that coinfection of HCV-infected patients with 
HGV does not influence the outcome of HCV- 
related hepatitis or the response to interferon ther- 
apy (8, 9). The aims of this study were (i) to study 
the prevalence of HGV infection in patients with 
chronic liver disease and in blood donors found 
positive for hepatitis B surface antigen (HBsAg) 
or anti-HCV; (ii) to examine whether HGV had 
an influence on HCV replication; and (iii) to an- 
alyze whether HGV/HCV coinfection influences 
the degree of liver disease. 
Patients and Methods. Data and sera from 254 pa- 
tients were analyzed. Of these patients, 100 had 
histologically proven chronic hepatitis C (Waidspi- 
tal Ztirich, Switzerland), 26 had primary biliary cir- 
rhosis, and 30 had alcoholic liver cirrhosis (Univer- 
sity Hospital of Heraklion, Greece). Samples 
from 47 anti-HCV-positive and 51 HBsAg-positive 
blood donors were also obtained from the Univer- 
sity Hospital of Heraklion, Greece. 
Total nucleic acids were extracted from serum ac- 
cording to published methods (10) and subjected 
to reverse transcriptase r action. For the detection 
of HGV sequences, two sets of primers were 
used. One set derives from the NS5a region (5'- 
CTC TTT GTG GTA GCC GAG AGA T-3', po- 
sition 6904 and 5'-CGA ATG AGT CAG AGG 
ACG GGG TAT-3' position 7059) and gives rise 
to a 156bp polymerase chain reaction (PCR) 
fragment, and the other derives from the 5'-non 
coding region (5'-NCR) (5'-CGG CCA AAA 
GGT GGT GGA TG-3' position 100, and 5'- 
CGA CGA GCC TGA CGT CGG G-3' position 
285) and gives rise to a 186bp PCR fragment. An 
Expand PCR system (Boehringer, Mannheim, 
Germany) was used, with 45 cycles of 1 min at 
94~ 1 rain and 25 sec at 55~ and 1 rain at 72~ 
To confirm the specificity of amplified products, 
and EIA PCR employing an EIA PCR labelling 
and detection system was used (Boehringer 
Mannheim). The specific probes for the hybridi- 
zation were biotinylated at the 5'-end. The probe 
for the NS5a region was 5'-biotin-GTT ACT 
GAG AGC AGC TCA GAT-3' position NS5a 152- 
172 and for the 5'-NCR region 5'-biotin-GGT 
AGC CACTAT AGG TGG G-3'.As positive con- 
trol HGV, ribonucleic acid (RNA) transcripts 
were used, a generous gift from Genelabs Technol- 
ogies, USA. Values higher than the cutoff level (3 
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Table 1: Characteristics of 100 patients with chronic hepatitis C. 
Characteristics 
Patients coinfected Patients infected 
with HGWHCV with HCV only 
(n = 18) (n = 82) 
Total 
(n = 100) 
P value 
Risk factor; no. (%) 
Intravenous drug use 11 (32) 23 (68) 
Transfusion 3 (25) 9 (75) 
None 4 (8) 50 (92) 
Mean age in years (• SD) 37 (27-68) 46 (26-83) 
Mean ALT level in U/ml (_+ SD) 133 + 78 108 _+ 103 
Mean HCV viral load in Eq/ml 264049 _+ 293635 301096 _+ 616829 
Genotype; no. (%) 
3a 6 (33) 12 (15) 
t b 5 (28) 29 (35) 
la  2 (11) 9 (11) 
Other/mixed infection 5 (28) 32 (39) 
34 (34) 
12 (12) 
54 (54) 
44 (26-83) 
18 
34 
11 
37 
0.05 a 
0.09 a 
0.3 a 
a Wilcoxon test. 
ALT, alanine aminotransferase. 
times the mean value of 3 negative controls) in the 
EIA PCR assay were defined as positive. 
The HCV viral load was measured using the Am- 
pticor system (Roche, Switzerland). Antibodies 
against HCV and HBsAg were detected by immu- 
noassays. Histological examination was per- 
formed using standard criteria, with fibrosis as- 
sessed semiquantitatively (11). The Innolipa strip 
assay (Innogenetics, Belgium) was used for detec- 
tion of HCV and analysis of genotype. For the sta- 
tistical analysis, the Yates corrected chi-square 
method and the Wilcoxon test were applied. 
Results and Discussion~ Of 100 patients with his- 
tologically proven chronic hepatitis C, 34 had 
used intravenous drugs, 12 had a history of trans- 
fusions, and the remaining 54 had no known risk 
factors (Table 1). Altogether, 18 of 100 (18%) 
HCV-infected patients were coinfected with 
HGV. The highest prevalence was found in intra- 
venous drug users (32%). Patients infected with 
HCV alone were older (p = 0.05). Thirty-three per- 
cent of coinfected patients but only 15% of pa- 
tients with HCV infection alone had HCV geno- 
type 3a, whereas 28% of coinfected and 35% of 
patients infected with HCV alone had genotype 
lb. Genotype la was found in an equal proportion 
of both groups (11%). Other genotypes, including 
infections with a mixture of genotypes, were 
found in 28% of coinfected patients and in 39% 
of patients with HCV infection alone. Ninety-four 
of the 100 patients had elevated ALT levels. Al- 
though HGV/HCV coinfected patients had 
slightly higher ALT levels, the difference was not 
significant (p = 0.09,Wilcoxon test, Table i and Fig- 
ure 1A). Virus load was slightly higher in patients 
with HCV infection alone, but the difference did 
not reach significance (p = 0.3, Wilcoxon test, Ta- 
ble 1 and Figure 1B). In both groups ALT and vi- 
rus load values were distributed over a broad 
range. Of the 18 patients coinfected with HGV and 
HCV, 16 (90 %) had histologically proven mild liv- 
er fibrosis; only two patients howed a severe fi- 
brosis. Both patients with severe liver fibrosis and 
HGV/HCV coinfection had a mixture of HCV 
genotypes. All six patients with genotype 3a, all 
five with genotype lb, and both with genotype la 
had mild fibrosis. Forty-seven of 82 (58 %) patients 
with HCV infection alone had mild fibrosis, and 
35 (42%) had severe fibrosis. The difference re- 
garding fibrosis in HGV/HCV versus HCV-infect- 
ed patients was statistically significant (p = 0.02, 
Yates corrected chi-square test). 
Twenty-six patients with primary biliary cirrhosis 
(median age 63 years, range 36-78 years) were an- 
alyzed. Only four individuals had elevated ALT 
levels. Histologically, eight patients had grade IV 
liver disease, four had grade III, seven grade II, 
and the remaining four grade I. Three of the 26 pa- 
tients were infected with HGV (11.5 %). However, 
ALT was elevated in only one HGV-infected pa- 
tient without severe disease. Thirty patients with 
alcoholic liver disease were examined, two of 
whom had elevated ALT levels but were infected 
with HCV. Hepatitis G virus was detected in four 
patients (13 %), all of whom had normal ALT lev- 
els. The histological degree of liver injury was not 
different in HGV positive or negative patients. 
Fifty-one HBsAg-positive and 47 anti-HCV-pos- 
itive blood donors were examined. Four of the 
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Figure 1: Alanine aminotransferase l vels and HCV viral load values in individual patients with chronic hepatitis C coinfect- 
ed with HGV or infected with HCV alone. Figure 1A shows the alanine aminotransferase l vels and 1B the viral load values. 
The mean value is indicated by a horizontal ine. Alanine aminotransferase is given in U/I and the viral load in equivalent vi- 
ral copies per milliliter. 
HBsAg-positive blood donors and two of the 
anti-HCV-positive donors had elevated ALT lev- 
els. Only one of 51 (2%) HBsAg-positive blood 
donors was HGV positive, with a normal ALT lev- 
el. In the group of anti-HCV-positive donors, five 
were HGV positive (10%), all of whom had nor- 
mal ALT levels. 
In this study we found that (i) HGV is prevalent 
in patients with chronic hepatitis C and different 
risk factors as well as in patients with other liver 
diseases; (ii) viremia did not differ significantly in 
HGV/HCV-coinfected versus HCV-infected pa- 
tients; and (iii) HGV/HCV coinfection was signif- 
icantly associated with mild fibrosis. 
The prevalence of HGV is higher in HCV-infect- 
ed patients with risk factors, such as intravenous 
drug use and transfusions (7,12). Interestingly, pa- 
tients infected with HGV were younger than pa- 
tients infected with HCV alone. Possibly, hepati- 
tis G, in contrast to hepatitis C, is a self-limited vi- 
ral infection that is cleared from the serum after 
a number of years, resulting in infection by HCV 
alone after years or decades. ~[lais hypothesis i  
supported by our previous finding that drug users 
who started intravenous heroin use before 1980 
had a lower prevalence of HGV than those who 
started after 1980 (7). Alternatively, this observa- 
tion may be explained by the notion that HGV 
was introduced only recently in these popula- 
tions. Hepatitis G virus and HCV share the paren- 
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teral mode of transmission, but the high preva- 
lence found in patients with alcoholic liver cirrho- 
sis, patients with primary biliary cirrhosis, and 
other low-risk groups investigated in our study 
suggests that other modes of transmission prob- 
ably occur. 
Virus load and ALT levels were slightly but not 
significantly different in HCV-infected versus 
HGV/HCV-coinfected patients. Possibly, as both vi- 
ruses belong to the Flaviviridae family and have a 
high degree of sequence homology, interferences 
may occur at many stages, e.g., at the replication 
level or during the production of viral proteins. In 
this study we found that HGV/HCV coinfection 
may lead to a rather mild course of liver disease. 
Similarly, Tanaka et al. (8) observed a tendency for 
less severe liver fibrosis in HGV/HCV-coinfected 
patients. Our observation, that all patients with 
HCV genotypes 3a and lb coinfected with HGV 
had only mild fibrosis, indicates that this difference 
is probably not due to genotypes, ince lb is usu- 
ally correlated with severe disease (13). 
One limitation of this study may be that the two 
groups of patients with chronic hepatitis, the one 
coinfected with HGV/HCV and the other with 
HCV alone, were different regarding age, mode of 
acquisition, and possibly other factors. This may 
have influenced our results regarding severity of 
fibrosis. In particular, the older age in the group 
of patients with HCV infection alone may have 
negatively influenced the degree of liver fibrosis. 
Neither ALT levels nor the severity of liver pathol- 
ogy was influenced in alcoholic liver disease or pri- 
mary biliary cirrhosis, suggesting that HGV infec- 
tion plays rather a secondary role in the develop- 
ment of these diseases, with no etiologic link. The 
higher prevalence of HGV infection among these 
patients as compared to the normal population 
may indicate that a liver with pathology enables 
the persistence of HGV infection. 
In conclusion, the data presented in this study sup- 
port the hypothesis that HGV infection does not 
worsen the outcome of HCV infection and may 
even have a favorable ffect. 
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